Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...

ALAMEDA, Calif., November 13, 2024--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a biopharmaceutical company developing miniaturized, long-acting drug implants, today reported ...

--Vivani Medical, Inc., a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced promising preclinical data for NPM-139, its subdermal ...

Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight subjects.

Vivani will assess changes in weight through a nine-week duration, with top-line data slated to be available in mid-2025. GLP-1RAs have become one of the dominant forces in the pharmaceutical sector.

Vivani Medical, Inc. VANI recently announced the filing of a Form 10 registration statement with the U.S. Securities and Exchange Commission (“SEC”), marking the first formal step toward ...

Vivani’s Chief Executive Officer Adam Mendelsohn, Ph.D., stated, "During the second quarter we achieved significant progress toward advancing the development of our proprietary, GLP-1 implants ...

Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical ...

Vivani president and CEO Dr Adam Mendelsohn said: “Preclinical weight loss and liver fat data announced earlier this year supports the potential for our GLP-1 implant to provide comparable ...

Vivani Medical shares surged more than five-fold in early trading on Wednesday after the drug developer said its experimental under-the-skin drug implant helped reduce weight in obese mice in a ...

Vivani’s Chief Executive Officer Adam Mendelsohn, Ph.D., stated, “We made significant progress advancing our proprietary GLP-1 implants for obesity and chronic weight management in the third ...

Vivani’s NPM-115 and NPM-119 are miniature, six-month, GLP-1 implants in development for the treatment of chronic weight management in obese or overweight patients and type 2 diabetes, respectively.